Exelixis Inc (EXEL)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$42.00

Buy

$44.00

arrow-up$0.19 (+0.45%)

Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
Prices updated at 29 May 2025, 09:01 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.39%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Stelios Papadopoulos,PhD
CEO
Dr. Michael M. Morrissey, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,147
Head office
1851 Harbor Bay Parkway
Alameda
United States
94502
mobile
+1 650 837-7000
letter
shubbard@exelixis.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. George H. Poste, D.V.M.,F.R.S.,PhD
Independent Director
0.10m--0.51m-
Mr. Jack L. Wyszomierski, M.S.
Independent Director
0.10m--0.51m-
Dr. Michael M. Morrissey, PhD
Director, President and Chief Executive Officer
1.25m--12.73m-
Dr. Stelios Papadopoulos,PhD
Chairman of the Board
0.13m--0.54m-
Mr. David E. Johnson
Independent Director
0.09m--0.49m-
Dr. Mary C. Beckerle, PhD
Independent Director
0.08m--1.16m-
Dr. Maria C. Freire, PhD
Independent Director
0.10m--0.51m-
Ms. Julie Anne Smith
Independent Director
0.10m--0.51m-
Mr. Jeffrey J. Hessekiel
Executive Vice President, General Counsel and Secretary
0.65m--4.45m-
Mr. Christopher J. Senner
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.79m--4.68m-
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
0.65m--4.45m-
Mr. Patrick J. Haley
Executive Vice President, Commercial
-----
Mr. Tomas J. Heyman
Independent Director
0.09m--0.50m-
Dr. Sue Gail Eckhardt, M.D.
Independent Director
0.08m--1.16m-
Dr. Dana T. Aftab, PhD
Chief Scientific Officer and Executive Vice President, Discovery and Translational Research
0.62m--3.90m-
Mr. Robert Oliver, M.B.A.
Independent Director
0.08m--0.49m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc30,356,9180.02354408670.13480330 Apr 202511.04
Vanguard Group Inc28,671,9870.01914-757265-2.57317130 Apr 202510.42
Farallon Capital Management, L.L.C.22,533,5004.63842-906000-3.8652730 Apr 20258.19
BlackRock Fund Advisors17,686,17313.62057-46718-30 Apr 20256.43
Renaissance Technologies Corp14,824,2650.82835-471600-3.08318630 Apr 20255.39

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
20 Dec 2024-Dr. Michael M. Morrissey, PhD--736,954--
20 Dec 2024-Dr. Michael M. Morrissey, PhD--1,587,000--
29 Nov 2024-Mr. Jeffrey J. Hessekiel--471,059--
29 Nov 2024-Mr. Jeffrey J. Hessekiel36.672,200,200486,059--
27 Nov 2024-Mr. Jeffrey J. Hessekiel18.802,431,103644,967--
27 Nov 2024-Mr. Jeffrey J. Hessekiel35.933,553,764546,059--
27 Nov 2024-Mr. Jeffrey J. Hessekiel-----
22 Nov 2024-Mr. Patrick J. Haley35.27352,700278,665--
15 Nov 2024-Dr. Michael M. Morrissey, PhD35.051,669,852916,742--
15 Nov 2024-Mr. Jeffrey J. Hessekiel35.05514,254515,653--
15 Nov 2024-Mr. Christopher J. Senner35.05613,585704,174--
15 Nov 2024-Dr. Amy C. Peterson, M.D.35.05954,201294,897--
18 Nov 2024-Mr. Patrick J. Haley34.31761,922308,046--
15 Nov 2024-Mr. Patrick J. Haley35.05514,254330,253--
18 Nov 2024-Mr. Patrick J. Haley34.41666,900288,665--
15 Nov 2024-Dr. Dana T. Aftab, PhD35.05449,972486,107--
05 Nov 2024-Dr. Dana T. Aftab, PhD18.801,823,337595,931--
05 Nov 2024-Dr. Dana T. Aftab, PhD-----
05 Nov 2024-Dr. Dana T. Aftab, PhD35.003,394,510498,945--
01 Nov 2024-Dr. George H. Poste, D.V.M.,F.R.S.,PhD34.001,020,000169,020--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.